Contents

Volume 87 Issue 9 | JNNP September 2016

Editorial commentary
915  Is Google good enough for medicine?  C S-Y Lin, W Haydn

Cerebrovascular disease


Movement disorders

958  Differences in globus pallidus neuronal firing rates and patterns related to different disease biolog in children with dystonia  V M McClelland, A Valentin, H G Rey, D E Lumsden, M C Elze, R Selway, G Alarcon, J-P Lin

968  Task-specific dystonia: pathophysiology and management  A Sadnicka, P Kassavetsis, I Pareès, A M Meppelink, K Butler, M Edwards

General neurology
975  Hippocampal dysfunction defines disease onset in Huntington’s disease  F Bechet, L C Schwab, S L Mason, R A Barker

Epilepsy
982  Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management  S P Mollan, F Ali, G Hassan-Smith, H Botfield, D I Friedman, A J Sinclair

Multiple sclerosis
937  Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation  B Weinstock-Guttman, J Hagemier, K S Kawak, V Saini, K Patrick, D P Ramsamy, M Nadeem, E Carl, D Hopnick, R Zwindon

944  Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity  F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavia, R B Bossio, V B Morra, G F Costantini, P Cavallia, D Centonze, G Comi, S Cotone, M Danni, A Francia, A Gafietto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosi, M Matta, M Minutella, E Montanon, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentinio, M Zappyna, on behalf of the SA.FE. study group

Epilepsy-related cytoarchitectonic abnormalities along white matter pathways  G R Glenn, J H Jensen, J A Helpern, M V Spampinato, R Kuzniecky, S S Keller, L Bondha

Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management  S P Mollan, F Ali, G Hassan-Smith, H Botfield, D I Friedman, A J Sinclair

Multiple sclerosis
937  Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation  B Weinstock-Guttman, J Hagemier, K S Kawak, V Saini, K Patrick, D P Ramsamy, M Nadeem, E Carl, D Hopnick, R Zwindon

944  Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity  F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavia, R B Bossio, V B Morra, G F Costantini, P Cavallia, D Centonze, G Comi, S Cotone, M Danni, A Francia, A Gafietto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosi, M Matta, M Minutella, E Montanon, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentinio, M Zappyna, on behalf of the SA.FE. study group

Epilepsy
930  Epilepsy-related cytoarchitectonic abnormalities along white matter pathways  G R Glenn, J H Jensen, J A Helpern, M V Spampinato, R Kuzniecky, S S Keller, L Bondha

Movement disorders

958  Differences in globus pallidus neuronal firing rates and patterns related to different disease biolog in children with dystonia  V M McClelland, A Valentin, H G Rey, D E Lumsden, M C Elze, R Selway, G Alarcon, J-P Lin

968  Task-specific dystonia: pathophysiology and management  A Sadnicka, P Kassavetsis, I Pareès, A M Meppelink, K Butler, M Edwards

General neurology
975  Hippocampal dysfunction defines disease onset in Huntington’s disease  F Bechet, L C Schwab, S L Mason, R A Barker

Epilepsy
982  Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management  S P Mollan, F Ali, G Hassan-Smith, H Botfield, D I Friedman, A J Sinclair

Multiple sclerosis
937  Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation  B Weinstock-Guttman, J Hagemier, K S Kawak, V Saini, K Patrick, D P Ramsamy, M Nadeem, E Carl, D Hopnick, R Zwindon

944  Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity  F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavia, R B Bossio, V B Morra, G F Costantini, P Cavallia, D Centonze, G Comi, S Cotone, M Danni, A Francia, A Gafietto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosi, M Matta, M Minutella, E Montanon, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentinio, M Zappyna, on behalf of the SA.FE. study group
Neurodegeneration
993  ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials
J Wang, V Logovinsky, S B Hendrix, S H Stanworth, C Perdomo, L Xu, S Dhadda, I Do, M Rabe, J Luthman, J Cummings, A Satlin

1000  Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer’s disease
N Mattsson, J M Schon, J Hardy, M R Turner, H Zetterberg

Neuro-inflammation
1005  Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

Neuro-oncology
1016  Molecular imaging of 1p/19q deletion in oligodendrogial tumours with 11C-methionine positron emission tomography
Y Iwadate, N Shinozaki, T Matsumi, Y Uchino, N Sacki

Neuromuscular
1022  Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?
T Prell, T M Ringer, K Wallenbold, P Garrison, A Gunkel, B Stubendorff, O W Win, J Grosskreutz

PostScript
1028  Letters